395 related articles for article (PubMed ID: 8959322)
1. Can hematuria be a predictor as well as a symptom or sign of bladder cancer?
Friedman GD; Carroll PR; Cattolica EV; Hiatt RA
Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):993-6. PubMed ID: 8959322
[TBL] [Abstract][Full Text] [Related]
2. Prospective external validation of a bladder cancer detection model.
Lotan Y; Svatek RS; Krabbe LM; Xylinas E; Klatte T; Shariat SF
J Urol; 2014 Nov; 192(5):1343-8. PubMed ID: 24859442
[TBL] [Abstract][Full Text] [Related]
3. Microscopic hematuria as a predictive factor for detecting bladder cancer at cystoscopy in women with irritative voiding symptoms.
Wu JM; Williams KS; Hundley AF; Jannelli ML; Visco AG
Am J Obstet Gynecol; 2006 May; 194(5):1423-6. PubMed ID: 16579943
[TBL] [Abstract][Full Text] [Related]
4. Prediagnostic toenail selenium and risk of bladder cancer.
Zeegers MP; Goldbohm RA; Bode P; van den Brandt PA
Cancer Epidemiol Biomarkers Prev; 2002 Nov; 11(11):1292-7. PubMed ID: 12433705
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of hematuria home screening for bladder cancer in men.
Cai T; Bartoletti R
Cancer; 2007 May; 109(9):1923-4; author reply 1924. PubMed ID: 17357998
[No Abstract] [Full Text] [Related]
6. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of hematuria home screening for bladder cancer in men.
Messing EM; Madeb R; Young T; Gilchrist KW; Bram L; Greenberg EB; Wegenke JD; Stephenson L; Gee J; Feng C
Cancer; 2006 Nov; 107(9):2173-9. PubMed ID: 17029275
[TBL] [Abstract][Full Text] [Related]
8. Bladder cancer in Sri Lanka: experience from a tertiary referral center.
Goonewardena SA; De Silva WA; De Silva MV
Int J Urol; 2004 Nov; 11(11):969-72. PubMed ID: 15509199
[TBL] [Abstract][Full Text] [Related]
9. Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample.
Hiatt RA; Ordoñez JD
Cancer Epidemiol Biomarkers Prev; 1994; 3(5):439-43. PubMed ID: 7848421
[TBL] [Abstract][Full Text] [Related]
10. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
[TBL] [Abstract][Full Text] [Related]
11. The significance of cystoscopy for the diagnosis of urothelial tumour.
Hattori R; Ohshima S; Ono Y; Miyake K
Int Urol Nephrol; 1993; 25(2):135-9. PubMed ID: 8365842
[TBL] [Abstract][Full Text] [Related]
12. [Hematuria due to polypoid cystitis. Its differential diagnosis from bladder carcinoma].
Gonzalvo Pérez V; Ramada Benlloch F; Blasco Alfonso E; Navalon Verdejo P; Sabater Marco V; Zaragoza Orts J
Arch Esp Urol; 1993 Jun; 46(5):424-6. PubMed ID: 8342981
[TBL] [Abstract][Full Text] [Related]
13. Early results of bladder-cancer screening in a high-risk population of heavy smokers.
Steiner H; Bergmeister M; Verdorfer I; Granig T; Mikuz G; Bartsch G; Stoehr B; Brunner A
BJU Int; 2008 Aug; 102(3):291-6. PubMed ID: 18336612
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of a bladder cancer screening program using home hematuria testing and molecular markers.
Bangma CH; Loeb S; Busstra M; Zhu X; El Bouazzaoui S; Refos J; Van Der Keur KA; Tjin S; Franken CG; van Leenders GJ; Zwarthoff EC; Roobol MJ
Eur Urol; 2013 Jul; 64(1):41-7. PubMed ID: 23478169
[TBL] [Abstract][Full Text] [Related]
15. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
[TBL] [Abstract][Full Text] [Related]
16. The clinical utility of atypical cytology is significantly increased in both screening and monitoring for bladder cancer when indexed with nuclear matrix protein-22.
Raina R; Pahlajani G; Ponsky LE; Agarwal A; Zippe CD
BJU Int; 2008 Aug; 102(3):297-300. PubMed ID: 18702780
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic tests in urology: urine cytology.
Lavallée LT; Fergusson D; Dahm P; Scales CD; Witiuk K; Breau RH
BJU Int; 2012 Dec; 110(11 Pt C):E789-91. PubMed ID: 23106855
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
[TBL] [Abstract][Full Text] [Related]
19. Screening for bladder tumours in men aged 60-70 years with a bladder tumour marker (UBC) and dipstick-detected haematuria using both white-light and fluorescence cystoscopy.
Hedelin H; Jonsson K; Salomonsson K; Boman H
Scand J Urol Nephrol; 2006; 40(1):26-30. PubMed ID: 16452052
[TBL] [Abstract][Full Text] [Related]
20. Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.
Ianari A; Sternberg CN; Rossetti A; Van Rijn A; Deidda A; Giannarelli D; Pansadoro V
Urology; 1997 May; 49(5):786-9. PubMed ID: 9145993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
